Position in BIOA
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$2,630,705
+$1,309,023 QoQ
Shares Held
107,332
+42.0% QoQ
Ownership
0.234%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#48
of 151 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 76%
Shared 0%
None 24%
Common Shares in BIOA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Bank of New York Mellon Corp holds $1,289,702,180 across 44 Drug Manufacturers - Specialty & Generic names. BIOA ranks #28 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
3,322,319 | $238,741,833 | |
| 2 | VTRS |
Viatris Inc
|
14,288,053 | $226,894,274 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
294,413 | $159,521,790 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
699,125 | $117,830,519 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
3,411,532 | $83,957,795 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,899,912 | $64,369,013 | |
| 7 | ALKS |
Alkermes plc.
|
1,097,282 | $57,497,573 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
441,831 | $49,016,724 |
All Filings in BIOA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,630,705 | 107,332 | Shares | Defined | 2026-08-06 | |
| 2026-03-31 | $1,321,682 | 75,568 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $814,437 | 61,560 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $341,025 | 57,998 | Shares | Defined | 2025-11-03 | |
| 2025-06-30 | $222,895 | 53,970 | Shares | Defined | 2025-08-05 | |
| 2025-03-31 | $80,966 | 21,534 | Shares | Defined | 2025-04-29 | |
| 2024-12-31 | $85,024 | 14,685 | Shares | Defined | 2025-02-04 | |
| No filing history on record for this holder in this stock. | ||||||